1. Home
  2. RC vs PRTC Comparison

RC vs PRTC Comparison

Compare RC & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ready Capital Corproation

RC

Ready Capital Corproation

HOLD

Current Price

$2.24

Market Cap

424.8M

Sector

Real Estate

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$16.91

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RC
PRTC
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
424.8M
386.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RC
PRTC
Price
$2.24
$16.91
Analyst Decision
Hold
Analyst Count
5
0
Target Price
$5.75
N/A
AVG Volume (30 Days)
3.1M
4.8K
Earning Date
11-06-2025
08-28-2025
Dividend Yield
20.92%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
N/A
$6,391,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$32.94
N/A
P/E Ratio
N/A
$7.77
Revenue Growth
N/A
1265.60
52 Week Low
$2.32
$13.30
52 Week High
$7.64
$23.35

Technical Indicators

Market Signals
Indicator
RC
PRTC
Relative Strength Index (RSI) 30.43 51.09
Support Level $2.37 $16.44
Resistance Level $2.53 $17.17
Average True Range (ATR) 0.13 0.35
MACD 0.00 0.12
Stochastic Oscillator 3.45 55.29

Price Performance

Historical Comparison
RC
PRTC

About RC Ready Capital Corproation

Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: